RecruitingNCT05150483
EndotyPIng PreHospitAl de Novo Acute hYpoxemic Respiratory Failure
Sponsor
Evangelismos Hospital
Enrollment
250 participants
Start Date
Dec 10, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
We attempt to perform dynamic endotyping of critically ill patients presenting in the emergency department with de novo acute hypoxemic respiratory failure (AHRF). We also attempt to identify what clinical, radiological, physiological and biological variables collected early in the course of AHRF correlate with subsequent mortality and/or persistent severe hypoxemia.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Adult patients (aged >18 years) presenting in the emergency department
- De novo acute hypoxemic respiratory failure (requiring oxygen flow rate of 5 liters per minute or more to maintain SpO2 of 90% or more)
Exclusion Criteria9
- Age <18 years
- Not admitted to the hospital
- Postoperative acute respiratory failure (within one week from surgery)
- Chronic hypoxemic respiratory failure (requiring long term oxygen therapy at home)
- Hypercapnic respiratory failure
- Transferred from another hospital or facility
- Pregnant women
- Admitted to the hospital purely to facilitate comfort care
- Lack of informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05150483
Related Trials
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
NCT065011181 location
Prediction of Inspiratory Effort Response to High PEEP in Patients Recovering From ARDS
NCT045240911 location
"Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress syndrOme"
NCT0681434011 locations
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT0670168236 locations
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT0670165636 locations